NR4A1 and breast carcinoma: On 24 May 2019, the Food and Drug Administration approved alpelisib (PIQRAY, Novartis Pharmaceuticals Corporation) in combination with fulvestrant in metastatic/advanced, hormone receptor-positive, HER2-negative breast cancers carrying PI3CA mutation, after progression from a first-line endocrine therapy.